Highlights in soft tissue sarcomas and gastrointestinal stromal tumours (GIST) trials reported at ASCO 2017 Annual Meeting

Research output: Contribution to journalComment/debate

1 Citation (Scopus)

Abstract

Herein, we summarise the results of the most relevant studies presented at the 2017 ASCO Annual Meeting in the field of soft tissue sarcomas (STSs) and gastrointestinal stromal tumours (GISTs). Innovations on the management of localised disease, highlights from the different experiences in the metastatic setting and large studies on rare histologies will be included. Special attention will be paid to results on immunotherapy, antiangiogenics use in histology with limited sensitivity to standard chemotherapy and new compounds. The preliminary results on the impact of the next generation sequencing in the everyday management of STS and GIST patients will be also discussed.

Original languageEnglish
Article number160
JournalBMC Medicine
Volume15
Issue number1
DOIs
Publication statusPublished - Aug 22 2017

Fingerprint

Gastrointestinal Stromal Tumors
Sarcoma
Histology
Disease Management
Immunotherapy
Drug Therapy

Keywords

  • Antiangiogenic drugs
  • Chemotherapy
  • Gastrointestinal stromal tumours
  • Immunotherapy
  • Next generation sequencing
  • Preoperative treatment
  • Prognostic assessment
  • Sarcoma

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{3b2cbaa0171c494c972a9a10b2d26127,
title = "Highlights in soft tissue sarcomas and gastrointestinal stromal tumours (GIST) trials reported at ASCO 2017 Annual Meeting",
abstract = "Herein, we summarise the results of the most relevant studies presented at the 2017 ASCO Annual Meeting in the field of soft tissue sarcomas (STSs) and gastrointestinal stromal tumours (GISTs). Innovations on the management of localised disease, highlights from the different experiences in the metastatic setting and large studies on rare histologies will be included. Special attention will be paid to results on immunotherapy, antiangiogenics use in histology with limited sensitivity to standard chemotherapy and new compounds. The preliminary results on the impact of the next generation sequencing in the everyday management of STS and GIST patients will be also discussed.",
keywords = "Antiangiogenic drugs, Chemotherapy, Gastrointestinal stromal tumours, Immunotherapy, Next generation sequencing, Preoperative treatment, Prognostic assessment, Sarcoma",
author = "Frezza, {Anna Maria} and Silvia Stacchiotti and Alessandro Gronchi",
year = "2017",
month = "8",
day = "22",
doi = "10.1186/s12916-017-0931-4",
language = "English",
volume = "15",
journal = "BMC Medicine",
issn = "1741-7015",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Highlights in soft tissue sarcomas and gastrointestinal stromal tumours (GIST) trials reported at ASCO 2017 Annual Meeting

AU - Frezza, Anna Maria

AU - Stacchiotti, Silvia

AU - Gronchi, Alessandro

PY - 2017/8/22

Y1 - 2017/8/22

N2 - Herein, we summarise the results of the most relevant studies presented at the 2017 ASCO Annual Meeting in the field of soft tissue sarcomas (STSs) and gastrointestinal stromal tumours (GISTs). Innovations on the management of localised disease, highlights from the different experiences in the metastatic setting and large studies on rare histologies will be included. Special attention will be paid to results on immunotherapy, antiangiogenics use in histology with limited sensitivity to standard chemotherapy and new compounds. The preliminary results on the impact of the next generation sequencing in the everyday management of STS and GIST patients will be also discussed.

AB - Herein, we summarise the results of the most relevant studies presented at the 2017 ASCO Annual Meeting in the field of soft tissue sarcomas (STSs) and gastrointestinal stromal tumours (GISTs). Innovations on the management of localised disease, highlights from the different experiences in the metastatic setting and large studies on rare histologies will be included. Special attention will be paid to results on immunotherapy, antiangiogenics use in histology with limited sensitivity to standard chemotherapy and new compounds. The preliminary results on the impact of the next generation sequencing in the everyday management of STS and GIST patients will be also discussed.

KW - Antiangiogenic drugs

KW - Chemotherapy

KW - Gastrointestinal stromal tumours

KW - Immunotherapy

KW - Next generation sequencing

KW - Preoperative treatment

KW - Prognostic assessment

KW - Sarcoma

UR - http://www.scopus.com/inward/record.url?scp=85027713115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027713115&partnerID=8YFLogxK

U2 - 10.1186/s12916-017-0931-4

DO - 10.1186/s12916-017-0931-4

M3 - Comment/debate

VL - 15

JO - BMC Medicine

JF - BMC Medicine

SN - 1741-7015

IS - 1

M1 - 160

ER -